<DOC>
	<DOC>NCT01807221</DOC>
	<brief_summary>To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it is safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic kidney disease or kidney disease alone. These treatment doses will be compared to eplerenone, another marketed drug approved to treat heart failure.</brief_summary>
	<brief_title>Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Ventricular Dysfunction, Left</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Men and women aged 18 years and older. The lower age limit may be higher if legally required in the participating country Women of childbearing potential can only be included in the study if a pregnancy test is negative and if they agree to use adequate contraception when sexually active Subjects with worsening chronic heart failure requiring emergency presentation to hospital and treatment with intravenous diuretics at hospital Subjects with clinical diagnosis of chronic heart failure (CHF) either ischemic or non ischemic, New York Heart Association (NYHA) functional class IIIV Subjects with type 2 diabetes mellitus and / or Subjects with 30 mL/min/1.73m2 &lt;/= eGFR &lt;/= 60 mL/min/1.73m2 (MDRD, Modification of Diet in Renal Disease Study Group) at screening Left ventricular ejection fraction (LVEF) &lt;/= 40% Blood potassium &lt;/= 5.0 mmol/L at screening Systolic blood pressure &gt;/= 90 mmHg without signs and symptoms of hypotension at the screening visit Acute denovo heart failure or acute inflammatory heart disease, e.g. acute myocarditis Acute coronary syndrome (ACS) in last 30 days prior to screening Cardiogenic shock Valvular heart disease requiring surgical intervention during the course of the study Stroke or transient ischemic cerebral attack in the last 3 months prior to the screening visit Concomitant treatment with any mineralocorticoid receptor antagonist (MRA), renin inhibitor, or potassiumsparing diuretic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart Decompensation</keyword>
</DOC>